《大行》中金升三生制药(01530.HK)目标价56.3% 维持“跑赢大市”评级

阿斯达克财经
22 May

中金发表研究报告指,三生制药(01530.HK) 将向辉瑞授予PD-1/VEGF双特异性抗体(SSGJ-707),在中国以外的开发、生产和商业化的独家许可。辉瑞将获中国市场商业化选择权。该行维持对三生制药今明两年的经调整盈利预测,分别为24.1亿及26亿元人民币,续予“跑赢大市”评级,并将目标价上调56.3%至21.1港元。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-21 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10